Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Ridgeback Capital Management is a private investment firm founded in 2006 by Dr. Wayne Holman. Based in New York City, the firm specializes in securities trading and long-term private investments, particularly in life science companies. Over the years, Ridgeback has established itself as a significant player in the biopharma sector, funding over 100 companies dedicated to developing innovative therapies.
The firm operates as an actively managed investment vehicle, combining public securities trading with private equity investments. Ridgeback's commitment to patient capital allows it to support innovators in the healthcare sector, ensuring they have the necessary resources to bring their solutions to market. The firm has a notable history of funding transformative medicines, including a collaboration on a COVID-19 treatment pill with Ridgeback Biotherapeutics.
Ridgeback Capital Management invests in both private and public companies focused on developing life-saving and life-changing therapies. The firm emphasizes the importance of patient capital, which it believes is crucial for the growth of new technologies in the healthcare sector. Ridgeback's investment strategy spans multiple stages, including Friends & Family, Angel, Pre-seed, Seed, Series A through Series F, and even Pre-IPO and IPO stages.
Geographically, Ridgeback operates globally, with a strong focus on North America. The firm primarily targets the biotech and healthcare sectors, seeking companies that address unmet medical needs. Ridgeback's long-horizon investment approach allows it to support innovators through various stages of development, ensuring they have the necessary backing to succeed.
Ridgeback Capital Management has a diverse portfolio of over 100 biopharma companies, showcasing its commitment to funding innovative therapies. Notable companies in its portfolio include:
These companies are at the forefront of developing therapies that address critical healthcare challenges, demonstrating Ridgeback's focus on impactful investments.
Wayne Holman, MD - Founder & CEO. Dr. Holman is a physician-investor with extensive experience in the life sciences sector. He co-founded Ridgeback Biotherapeutics and serves as Co-Chair of the Ridgeback-Merck Molnupiravir Joint Steering Committee. His core strategy revolves around providing patient capital to support innovators in life-saving therapeutics.
To pitch Ridgeback Capital Management, founders should send an email to info@ridgebackcap.com. It is essential to include a comprehensive pitch deck that outlines the business model, market opportunity, and team qualifications. Ridgeback prefers detailed information on the technology and its potential impact on healthcare.
Response times may vary, but founders should expect a thorough review process given the firm's focus on life sciences. Warm introductions can enhance the chances of a favorable response, so leveraging connections within the industry is advisable.
In early 2020, Ridgeback Capital Management made headlines for its involvement in the development of molnupiravir, an oral COVID-19 antiviral. The firm purchased an exclusive commercial license for the drug from Emory University and partnered with Merck & Co. for Phase 3 clinical trials. This collaboration led to the drug receiving Emergency Use Authorization (EUA) as a treatment for COVID-19.
Ridgeback continues to be active in funding transformative medicines aimed at addressing unmet medical needs, reinforcing its commitment to supporting life science innovations.
What are Ridgeback Capital's investment criteria?
Ridgeback Capital focuses on life science and biopharma companies that are developing life-saving and life-changing therapies. The firm invests across various stages, from early private investments to public equity positions.
How can I pitch to Ridgeback Capital?
Founders can reach out to Ridgeback Capital via email at info@ridgebackcap.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and team background.
What makes Ridgeback Capital different from other investors?
Ridgeback Capital emphasizes patient capital, which allows them to support companies over a longer investment horizon. This approach is particularly beneficial for life science companies that require time to develop their therapies.
What is Ridgeback Capital's geographic focus?
The firm operates globally, with a strong emphasis on North America. This broad geographic focus allows Ridgeback to tap into various markets and opportunities in the biotech and healthcare sectors.
What is the typical check size for investments?
Ridgeback Capital invests across a wide range of stages, which means check sizes can vary significantly. The firm participates in funding rounds from Friends & Family to Series E and beyond, adapting its investment size to the specific needs of each company.
What kind of support does Ridgeback Capital provide to its portfolio companies?
Ridgeback Capital adds value through patient capital, strategic guidance, and access to a network of industry experts. The firm’s leadership, particularly Dr. Wayne Holman, leverages extensive experience in the life sciences sector to support the growth and success of its investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.